{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:35:23Z","timestamp":1791362123521,"version":"4.3.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20202ABCL206002"],"award-info":[{"award-number":["20202ABCL206002"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20202ABCL206002"],"award-info":[{"award-number":["20202ABCL206002"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20202ABCL206002"],"award-info":[{"award-number":["20202ABCL206002"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20202ABCL206002"],"award-info":[{"award-number":["20202ABCL206002"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20202ABCL206002"],"award-info":[{"award-number":["20202ABCL206002"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20202ABCL206002"],"award-info":[{"award-number":["20202ABCL206002"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endothelial dysfunction is characterized by an imbalance between endothelium-derived vasodilatory and vasoconstrictive effects and may play an important role in the development of heart failure. An increasing number of studies have shown that endothelial-derived NO-mediated vasodilation is attenuated in heart failure patients. However, the role of endothelin-1 (ET-1) in heart failure remains controversial due to its different receptors including ET-1 receptor type A (ETAR) and ET-1 receptor type B (ETBR). The aim of this study was to determine whether ET-1 and its receptors are activated and to explore the role of ETAR and ETBR in heart failure induced by myocarditis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We constructed an animal model of experimental autoimmune myocarditis (EAM) with porcine cardiac myosin. Twenty rats were randomized to the control group (3\u00a0weeks,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), the extended control group (8\u00a0weeks,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), the EAM group (3\u00a0weeks,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), the extended EAM group (8\u00a0weeks,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095). HE staining was used to detect myocardial inflammatory infiltration and the\u00a0myocarditis score, Masson\u2019s trichrome staining was used to assess myocardial fibrosis, echocardiography was used to evaluate cardiac function, ELISA was used to detect serum NT-proBNP and ET-1 concentrations, and immunohistochemistry and western blotting were used to detect ETAR and ETBR expression in myocardial tissue of EAM-induced heart failure. Subsequently, a model of myocardial inflammatory injury in vitro was constructed to explore the role of ETAR and ETBR in EAM-induced heart failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>EAM rats tended to reach peak inflammation after 3\u00a0weeks of immunization and developed stable chronic heart failure at 8\u00a0weeks after immunization. LVEDd and LVEDs were significantly increased in the EAM group compared to the control group at 3\u00a0weeks and 8\u00a0weeks after immunization while EF and FS were significantly reduced. Serum NT-proBNP concentrations in EAM (both 3\u00a0weeks and 8\u00a0weeks) were elevated. Therefore, EAM can induce acute and chronic heart failure due to myocardial inflammatory injury. Serum ET-1 concentration and myocardial ETAR and ETBR protein were significantly increased in EAM-induced heart failure in vivo. Consistent with the results of the experiments in vivo, ETAR and ETBR protein expression levels were significantly increased in the myocardial inflammatory injury model in vitro. Moreover, ETAR gene silencing inhibited inflammatory cytokine TNF-\u03b1 and IL-1\u03b2 levels, while ETBR gene silencing improved TNF-\u03b1 and IL-1\u03b2 levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ET-1, ETAR, and ETBR were activated in both EAM-induced acute heart failure and chronic heart failure. ETAR may positively regulate EAM-induced heart failure by promoting myocardial inflammatory injury, whereas ETBR negatively regulates EAM-induced heart failure by alleviating myocardial inflammatory injury.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-023-03658-1","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T14:02:58Z","timestamp":1704204178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Activation of ETAR and ETBR in myocardial tissue characterizes heart failure induced by experimental autoimmune myocarditis"],"prefix":"10.1186","volume":"24","author":[{"given":"Peng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangfeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"2","key":"3658_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jaccas.2020.01.004","volume":"2","author":"TS Kafil","year":"2020","unstructured":"Kafil TS, Tzemos N. Myocarditis in 2020: Advancements in Imaging and Clinical Management. JACC Case Rep. 2020;2(2):178\u20139.","journal-title":"JACC Case Rep"},{"key":"3658_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fcvm.2019.00064","volume":"6","author":"P B\u0142yszczuk","year":"2019","unstructured":"B\u0142yszczuk P. Myocarditis in Humans and in Experimental Animal Models. Front Cardiovasc Med. 2019;6:64.","journal-title":"Front Cardiovasc Med"},{"key":"3658_CR3","doi-asserted-by":"publisher","first-page":"107155","DOI":"10.1016\/j.carpath.2019.107155","volume":"44","author":"D Razzano","year":"2020","unstructured":"Razzano D, Fallon JT. Myocarditis: somethings old and something new. Cardiovasc Pathol. 2020;44:107155.","journal-title":"Cardiovasc Pathol"},{"issue":"3","key":"3658_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","volume":"18","author":"C Tsch\u00f6pe","year":"2021","unstructured":"Tsch\u00f6pe C, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18(3):169\u201393.","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"3658_CR5","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.mayocp.2016.05.013","volume":"91","author":"G Sinagra","year":"2016","unstructured":"Sinagra G, et al. Myocarditis in Clinical Practice. Mayo Clin Proc. 2016;91(9):1256\u201366.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"3658_CR6","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1161\/HYPERTENSIONAHA.119.12105","volume":"74","author":"M Barton","year":"2019","unstructured":"Barton M, Yanagisawa M. Endothelin: 30 Years From Discovery to Therapy. Hypertension. 2019;74(6):1232\u201365.","journal-title":"Hypertension"},{"issue":"2","key":"3658_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/CIRCRESAHA.116.306531","volume":"119","author":"PM Vanhoutte","year":"2016","unstructured":"Vanhoutte PM, et al. Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator. Circ Res. 2016;119(2):375\u201396.","journal-title":"Circ Res"},{"issue":"2","key":"3658_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ccc.2019.12.009","volume":"36","author":"AR Cyr","year":"2020","unstructured":"Cyr AR, et al. Nitric Oxide and Endothelial Dysfunction. Crit Care Clin. 2020;36(2):307\u201321.","journal-title":"Crit Care Clin"},{"key":"3658_CR9","doi-asserted-by":"crossref","unstructured":"Alem MM. Endothelial dysfunction in chronic heart failure: Assessment, findings, significance, and potential therapeutic targets. Int J Mol Sci. 2019;20(13):3198.","DOI":"10.3390\/ijms20133198"},{"issue":"1","key":"3658_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10741-019-09881-3","volume":"25","author":"C Zuchi","year":"2020","unstructured":"Zuchi C, et al. Role of endothelial dysfunction in heart failure. Heart Fail Rev. 2020;25(1):21\u201330.","journal-title":"Heart Fail Rev"},{"issue":"6","key":"3658_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/FJC.0b013e31813c6cc3","volume":"50","author":"M Iglarz","year":"2007","unstructured":"Iglarz M, Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol. 2007;50(6):621\u20138.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"3658_CR12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/FJC.0000000000000283","volume":"66","author":"M Iglarz","year":"2015","unstructured":"Iglarz M, et al. Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors. J Cardiovasc Pharmacol. 2015;66(4):332\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"key":"3658_CR13","doi-asserted-by":"publisher","first-page":"104269","DOI":"10.1016\/j.phrs.2019.104269","volume":"146","author":"J Wu","year":"2019","unstructured":"Wu J, et al. Protosappanin A protects against experimental autoimmune myocarditis, and induces metabolically reprogrammed tolerogenic DCs. Pharmacol Res. 2019;146:104269.","journal-title":"Pharmacol Res"},{"issue":"5","key":"3658_CR14","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/ehf2.12767","volume":"7","author":"R Pistulli","year":"2020","unstructured":"Pistulli R, et al. Characterization of dendritic cells in human and experimental myocarditis. ESC Heart Fail. 2020;7(5):2305\u201317.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"3658_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1248\/bpb.33.477","volume":"33","author":"Y Sanzen","year":"2010","unstructured":"Sanzen Y, et al. Functional proteomic analysis of experimental autoimmune myocarditis-induced chronic heart failure in the rat. Biol Pharm Bull. 2010;33(3):477\u201386.","journal-title":"Biol Pharm Bull"},{"key":"3658_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tox.2019.04.011","volume":"422","author":"R Wang","year":"2019","unstructured":"Wang R, et al. Leonurine alleviates LPS-induced myocarditis through suppressing the NF-\u043aB signaling pathway. Toxicology. 2019;422:1\u201313.","journal-title":"Toxicology"},{"issue":"2","key":"3658_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/cvr\/cvab015","volume":"118","author":"M Mirna","year":"2022","unstructured":"Mirna M, et al. A new player in the game: treatment with antagomiR-21a-5p significantly attenuates histological and echocardiographic effects of experimental autoimmune myocarditis. Cardiovasc Res. 2022;118(2):556\u201372.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"3658_CR18","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.4049\/jimmunol.1103610","volume":"189","author":"K Tajiri","year":"2012","unstructured":"Tajiri K, et al. Suppressor of cytokine signaling 1 DNA administration inhibits inflammatory and pathogenic responses in autoimmune myocarditis. J Immunol. 2012;189(4):2043\u201353.","journal-title":"J Immunol"},{"key":"3658_CR19","unstructured":"Bozkurt B, Coats A, Tsutsui H. Universal definition and classification of heart failure. J Card Fail. 2021;7:S1071-9164(21)00050-6."},{"issue":"3","key":"3658_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","volume":"114","author":"KM Harris","year":"2006","unstructured":"Harris KM, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216\u201325.","journal-title":"Circulation"},{"issue":"11","key":"3658_CR21","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ejhf.1236","volume":"20","author":"MG Crespo-Leiro","year":"2018","unstructured":"Crespo-Leiro MG, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505\u201335.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"3658_CR22","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/ehf2.12555","volume":"6","author":"D Tomasoni","year":"2019","unstructured":"Tomasoni D, et al. Highlights in heart failure. ESC Heart Fail. 2019;6(6):1105\u201327.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"3658_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10741-020-09987-z","volume":"27","author":"F Triposkiadis","year":"2022","unstructured":"Triposkiadis F, et al. Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. Heart Fail Rev. 2022;27(1):337\u201344.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"3658_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.hfc.2021.05.010","volume":"17","author":"D Stolfo","year":"2021","unstructured":"Stolfo D, Collini V, Sinagra G. Advanced Heart Failure in Special Population: Cardiomyopathies and Myocarditis. Heart Fail Clin. 2021;17(4):661\u201372.","journal-title":"Heart Fail Clin"},{"issue":"3","key":"3658_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1113\/expphysiol.2007.040469","volume":"93","author":"L Ray","year":"2008","unstructured":"Ray L, et al. Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure. Exp Physiol. 2008;93(3):434\u201342.","journal-title":"Exp Physiol"},{"issue":"4","key":"3658_CR26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3109\/08037059709062077","volume":"6","author":"ML Sirvi\u00f6","year":"1997","unstructured":"Sirvi\u00f6 ML, et al. Endothelin-1 in heart and pulmonary tissue in experimental heart failure. Blood Press. 1997;6(4):250\u20135.","journal-title":"Blood Press"},{"issue":"6","key":"3658_CR27","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1161\/01.CIR.82.6.2226","volume":"82","author":"KB Margulies","year":"1990","unstructured":"Margulies KB, et al. Increased endothelin in experimental heart failure. Circulation. 1990;82(6):2226\u201330.","journal-title":"Circulation"},{"key":"3658_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/bs.apha.2016.05.002","volume":"77","author":"M Houde","year":"2016","unstructured":"Houde M, Desbiens L, D\u2019Orl\u00e9ans-Juste P. Endothelin-1: Biosynthesis, Signaling and Vasoreactivity. Adv Pharmacol. 2016;77:143\u201375.","journal-title":"Adv Pharmacol"},{"key":"3658_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.reprotox.2015.06.048","volume":"56","author":"MA de Raaf","year":"2015","unstructured":"de Raaf MA, et al. Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension. Reprod Toxicol. 2015;56:45\u201351.","journal-title":"Reprod Toxicol"},{"issue":"10","key":"3658_CR30","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2165\/00003495-200464100-00001","volume":"64","author":"G Ertl","year":"2004","unstructured":"Ertl G, Bauersachs J. Endothelin receptor antagonists in heart failure: current status and future directions. Drugs. 2004;64(10):1029\u201340.","journal-title":"Drugs"},{"issue":"21","key":"3658_CR31","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","volume":"98","author":"G S\u00fctsch","year":"1998","unstructured":"S\u00fctsch G, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98(21):2262\u20138.","journal-title":"Circulation"},{"key":"3658_CR32","doi-asserted-by":"crossref","unstructured":"Valero-Munoz M, et al. Dual endothelin-A\/endothelin-B receptor blockade and cardiac remodeling in heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9(11):e003381.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003381"},{"issue":"27","key":"3658_CR33","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"issue":"5","key":"3658_CR34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1253\/circj.CJ-20-1104","volume":"85","author":"HI Choi","year":"2021","unstructured":"Choi HI, et al. Effects of Age, Sex, and Obesity on N-Terminal Pro B-Type Natriuretic Peptide Concentrations in the General Population. Circ J. 2021;85(5):647\u201354.","journal-title":"Circ J"},{"issue":"2","key":"3658_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","volume":"27","author":"V Castiglione","year":"2022","unstructured":"Castiglione V, et al. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022;27(2):625\u201343.","journal-title":"Heart Fail Rev"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03658-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-023-03658-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03658-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T14:06:54Z","timestamp":1704204414000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-023-03658-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3658"],"URL":"https:\/\/doi.org\/10.1186\/s12872-023-03658-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2534098\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All protocols in this study were approved by the Institutional Animal Care and Use Committee of The First Affiliated Hospital, Jiangxi Medical College, Nanchang University (IACUC Issue No: 202205QR004), in compliance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no.85\u201323, revised 1996). All methods in our manuscript are reported in accordance with ARRIVE guidelines (\n                      \n                      ) for the reporting of animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}